MAVS pathway by direct administration into the tumor. We performed the phase I dose escalation safety/tolerability and preliminary efficacy study of intra-tumoral and subcutaneous administration of HVJ-E in patients suffering from chemotherapy-resistant malignant pleural mesothelioma. Method: We performed the dose upward titration clinical study for checking the safety, drug tolerance, and preliminary efficacy of the intra-tumoral and subsequent subcutaneous administration of HVJ-E. We administrated HVJ-E to the patients 4 times per 2 weeks (the first was intra-tumoral, and residual 3 times were subcutaneous injection), and then washed out the drug from the body for 2 weeks. This cycle was repeated 2 times. We observed the patients for 8 weeks, and evaluated them by CTCAE, modified RECIST, and PERCIST. Result: Three patients were enrolled as a low-dose group, and three patients were enrolled as a high-dose group. There was no discontinuation of the administration due to the severe adverse events. Results; The mean disease duration from confirmed diagnosis to this trial was 2.27 years (0.6-4.5 years). We defined the primary endpoint as an assessment of dose limiting toxicity related with HVJ-E. Neither serious adverse events (SAE) nor DLT were observed during the observation period.
P1.14-20 The Expression of DNA Methylation of GAD1 Gene is an Indicator of Malignant Behavior in Thymic Epithelial Tumor K. Kondo, 1 S. Soejima, 1 N. Wusiman, 1 R. Kishibuchi, 1 M. Tsuboi, 2 K. Kajiura, 2 Y. Kawakami, 2 N. Kawakita, 2 T. Sawada, 2 H. Toba, 3 M. Yoshida, 3 H. Takizawa, 2 A. Tangoku 2 1 Department of Oncological Medical Services, Graduate School of Biomedical Sciences, Tokushima University, Tokushima/JP, 2 Thoracic, Endocrine and Oncological Surgery, Graduate School of Biomedical Sciences, Tokushima University, Tokushima/JP, 3 Department of Thoraci,endocrine Surgery and Oncology, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima City/JP Background: Genome-wide screening for aberrantly methylated CpG islands was performed in 7 thymic carcinoma (TC) samples and 8 type-B3 thymoma samples using HumanMethylation450 K BeadChip (Illumina, Santa Clara, CA, USA) analysis. We identified 22 genes as commonly hypermethylated in TC comparing with B3 thymoma. GAD1 (glutamic acid decarboxylase 1)was one of the most significant hypermethylated genes in TC. GAD1 is the enzyme that synthesizes GABA. Recent some reports showed that it is significantly increased in neoplastic tissues. However, the mechanism underlying this increase remains elusive. In this study, we examine mRNA and protein expressions and DNA methylation of GAD1 in thymic epithelial tumors (TETs). Method: In total, 49 thymic tumour samples (A; 5, AB; 2, B1; 4, B2; 11, B3; 9, carcinoma; 18) and 20 paired normal tissues were obtained from patients with histologically proven TET, who underwent surgery at the Tokushima University Hospital (Tokushima, Japan) between 1990 and 2016. The methylation status of thymic epithelial tumor samples was validated by pyrosequencing in a larger cohort. The expression status was analysed by quantitative polymerase chain reaction (PCR) and immunohistochemistry (IHC). Result: The previous study (Oncogene 2015, 1e14) showed that the key locus responsible for GAD1 reactivation was mapped to a DNA methylation-sensitive CTCF-binding site (CTCF-BS3) within the third intron of GAD1. We targeted this region for pyrosequencing. Pyrosequencing confirmed that DNA methylation of GAD1 gene of TC was significantly higher than that of thymoma (36.5% versus 7.3%, p<0.001), and that DNA methylation of GAD1 gene of thymoma was similar to that of normal thymus (7.3% vs 8.6%). Quantitative PCR and IHC staining revealed that GAD1 mRNA and protein expression levels of TC were higher than those of thymoma (RT-PCR; 8.84 vs 0.72). There were not differences of DNA methylation and expression of GAD1 among subtype of thymoma according to WHO histologic classification. There was a tendency of hypermethylated GAD1 gene in Stage IV comparing with other Stage (Masaoka's clinical staging). Conclusion: TC frequently had DNA methylation of CTCFbinding site 3 in GAD1 gene, and high levels of mRNA and protein of GAD1. GAD1 may represent an epigenetic therapeutic target in TC. Keywords: DNA methylation, GAD1, Thymic carcinoma P1.14-21 Circulating Biomarkers in Thymic Epithelial Tumors D. Valdivia, 1 D. Cheufou, 1 B. Fels, 1 S. Puhlvers, 1 G. Weinreich, 1 D. Theegarten, 2 T. Plönes, 1 K. Mardanzai, 1 M. Zaatar, 1 B. Hegedus, 1 G. Stamatis, 1 C. Aigner 1 1 Department of Thoracic Surgery, Ruhrlandklinik, University Clinic Essen, Essen/DE, 2 Department of Pathology, University Clinic Essen, Essen/DE Background: Thymic epithelial tumors are the most common mediastinal tumors. Surgery is the mainstay of treatment and complete resection provides the best survival rate. Nevertheless, advanced tumors may require multimodal therapy and additional prognostic factors beyond tumor stage and histological classification might help to risk-stratify patients and personalize the treatment course. Method: Between 1999 and 2017 202 patients with thymic epithelial tumors were operated in our center. The preoperative C-reactive protein (CRP) and lactate dehydrogenase (LDH) levels as well as clinical follow-up were retrospectively collected and the association of circulating biomarkers with clinicopathological parameters and their impact on overall survival was analyzed. Result: 115 male and 87 female patients were included in the study with 59.5 (±13.1) years mean age at the time of operation. 30 patients (including 12 male patients) suffered from myasthenia gravis. Thymic carcinoma was associated with high CRP (> 1mg/dl) when compared to thymoma cases (34% vs 12%, p¼0.001). While LDH levels did not show such association, there was a strong tendency for increased mean LDH levels in Masaoka 4 patients (252.5±18.9 vs 220.5±6.1, p¼0.063). Overall survival was analyzed in the thymic carcinoma subcohort. 90% of the patients were treated in a multimodal approach and received chemo-and/or radiotherapy in adjuvant or neoadjuvant setting. Median overall survival was 11.3 years. The Masaoka stage (1-3 versus 4) was a significant prognostic factor (HR 0.23, 95%CI 0.07 to 0.77, p¼0.017). Elevated CRP (> 1mg/ dl) did not show prognostic power for overall survival (HR 0.82, 95%CI 0.77 to 1.33, p¼0.76). In contrast increased preoperative LDH level (>200 U/L) resulted in poorer outcome (HR 0.32, 95%CI 0.09 to 1.13, p¼0.076). Conclusion: Circulating biomarkers show association with advanced disease stage in thymic epithelial tumors. Importantly, preoperative LDH levels carry prognostic information in thymic carcinoma and could be used to risk stratify surgically treated patients in multimodal treatment settings. Keywords: LDH, Thymic carcinoma, Thymoma
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